Brimonidine Tartrate for the Treatment of Injection Related Erythema

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 29, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Relapsing-Remitting Multiple Sclerosis (RRMS)
Interventions
DRUG

peginterferon beta-1a

SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29

DRUG

brimonidine tartrate

Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.

DRUG

Vehicle Gel

Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY